NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

HUMA

Humacyte Inc

Jun 20 • 04:00PM ET

2.31

Dollar change -0.05
Percentage change -2.12	%

Healthcare • Biotechnology • USA • NASD

Peers: MDXG NVRO CRBP ATEC AXGN ARCT RGEN XGN MIRM ZLAB

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT CBSE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.69	Insider Own	18.94%	Shs Outstand	155.12M	Perf Week	-4.15%
Market Cap	358.32M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.36%	Shs Float	125.45M	Perf Month	-7.23%
Enterprise Value	377.54M	PEG	-	EPS next Q	-0.16	Inst Own	39.88%	Short Float	25.35%	Perf Quarter	-27.36%
Income	-80.04M	P/S	689.08	EPS this Y	80.49%	Inst Trans	44.37%	Short Ratio	6.52	Perf Half Y	-46.77%
Sales	0.52M	P/B	9.94	EPS next Y	-14.69%	ROA	-49.40%	Short Interest	31.80M	Perf YTD	-54.26%
Book/sh	0.23	P/C	5.69	EPS next 5Y	-	ROE	-257.38%	52W Range	1.15 - 9.79	Perf Year	-62.68%
Cash/sh	0.41	P/FCF	-	EPS past 3/5Y	-23.74% 42.43%	ROIC	-70.48%	52W High	-76.40%	Perf 3Y	-40.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-1335.59%	52W Low	100.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	726.04	EPS Y/Y TTM	31.64%	Oper. Margin	-21470.79%	Volatility	2.50% 3.35%	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.28	Sales Y/Y TTM	-100.00%	Profit Margin	-15481.62%	RSI (14)	48.99	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	3.68	EPS Q/Q	194.67%	SMA20	-8.53%	Beta	2.00	Target Price	9.43
Payout	-	Debt/Eq	2.28	Sales Q/Q	-	SMA50	17.99%	Rel Volume	0.54	Prev Close	2.36
Employees	220	LT Debt/Eq	2.15	Earnings	May 13 BMO	SMA200	-38.99%	Avg Volume	4.88M	Price	2.31
IPO	Dec 01, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	246.83% -32.40%	Trades		Volume	2,637,255	Change	-2.12%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Resumed	H.C. Wainwright	Buy	$4
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$12 → $15
Dec-11-23	Initiated	H.C. Wainwright	Buy	$6
Aug-14-23	Upgrade	Piper Sandler	Underweight → Neutral	$2.75 → $3.50
Jun-22-23	Initiated	Cantor Fitzgerald	Overweight	$6
May-16-22	Downgrade	Piper Sandler	Overweight → Underweight	$10 → $4
Oct-29-21	Initiated	Cowen	Outperform	$17
Sep-24-21	Initiated	Oppenheimer	Outperform	$16
Sep-22-21	Initiated	BTIG Research	Buy	$19
Sep-16-21	Initiated	Piper Sandler	Overweight	$17

Jun-18-25 06:00PM	Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know (Zacks)
Jun-09-25 08:00AM	Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting (GlobeNewswire)
Jun-02-25 08:00AM	Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 (GlobeNewswire)
May-30-25 09:30AM	Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
May-19-25 04:05PM	Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq (GlobeNewswire) +11.66%
08:45AM	Loading…
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +31.06%
07:30AM	Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 08:00AM	Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 (GlobeNewswire)
Apr-30-25 06:00PM	Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
12:00PM	All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy (Zacks)
Apr-24-25 06:00PM	Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
Apr-16-25 06:15PM	Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know (Zacks) +8.39%
Apr-03-25 06:00PM	Humacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should Know (Zacks) -6.90%
Mar-29-25 12:05PM	Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz (TipRanks)
10:40AM	Humacyte price target lowered to $8 from $10 at BTIG (TipRanks)
01:48PM	Loading…
Mar-28-25 01:48PM	Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript (Seeking Alpha)
07:30AM	Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-26-25 04:28PM	Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel (SeekingAlpha) -30.43%
09:30AM	Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet (Zacks)
08:00AM	Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 (GlobeNewswire)
Mar-25-25 08:35PM	Humacyte, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -13.40%
04:01PM	Humacyte, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-24-25 06:00PM	Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know (Zacks)
10:42AM	Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) (SeekingAlpha)
Mar-10-25 08:00AM	Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics (GlobeNewswire) -6.15%
Mar-06-25 08:00AM	Trestle Bio Announces Research Collaboration with Humacyte (Business Wire) -6.03%
Mar-03-25 08:00AM	Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 (GlobeNewswire) -10.15%
Feb-27-25 04:05PM	Humacyte to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
08:00AM	Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess and Other Bioengineered Tissues (GlobeNewswire)
Feb-26-25 08:00AM	Humacyte Announces Commercial Launch of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma (GlobeNewswire) +12.83%
08:00AM	Loading…
Jan-28-25 08:00AM	Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP ) Development Using iPSCs (GlobeNewswire)
Jan-21-25 08:00AM	Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV for Coronary Artery Bypass Grafting (GlobeNewswire)
Jan-17-25 05:14AM	Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA (PR Newswire)
Jan-13-25 12:02PM	Humacyte, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights HUMA (GlobeNewswire)
08:00AM	Humacyte Provides Update on Commercial Launch and Pricing of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma (GlobeNewswire)
Jan-03-25 05:30AM	Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA (PR Newswire)
Jan-02-25 10:07AM	Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA (PR Newswire)
Dec-24-24 08:25AM	Humacyte price target raised to $17 from $15 at Benchmark (TipRanks)
Dec-19-24 10:47PM	Humacyte Announces FDA Approval of SYMVESS (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma (GlobeNewswire) +34.10%
01:24PM	Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles Hagens Berman (GlobeNewswire)
Dec-16-24 03:36PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire) +5.85%
01:45PM	Investors in Humacyte, Inc. Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights HUMA (GlobeNewswire)
Dec-12-24 11:48AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
Dec-11-24 01:00PM	Investors in Humacyte, Inc. Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights HUMA (GlobeNewswire)
12:20PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman (Newsfile)
Dec-09-24 01:32PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire) -12.73%
Dec-06-24 05:52AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman (Newsfile) +7.57%
Dec-05-24 11:08AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
Dec-02-24 03:05PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
09:05AM	Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
05:45AM	Shareholders of Humacyte, Inc. Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA (PR Newswire)
Nov-28-24 10:41AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
Nov-22-24 08:30AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman (Newsfile)
08:00AM	Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) (GlobeNewswire)
Nov-21-24 08:00AM	Humacyte Clinical Results Highlighting Benefit of the ATEV in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery (GlobeNewswire)
Nov-18-24 08:00AM	Humacyte Presents Preclinical Results of Small-Diameter ATEV for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 (GlobeNewswire) -8.07%
Nov-15-24 01:32PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
Nov-14-24 08:00AM	Humacyte Announces Pricing of $15.0 Million Registered Direct Offering (GlobeNewswire) -9.36%
Nov-11-24 04:37PM	Humacyte (HUMA) Faces Questions After FDA Inspection Hagens Berman (GlobeNewswire)
Nov-08-24 09:16AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire) +9.89%
08:00AM	Humacyte Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-06-24 08:00AM	Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024 (GlobeNewswire)
Nov-04-24 06:34PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire) -5.94%
Oct-31-24 02:16PM	Humacyte (HUMA) Faces Questions After FDA Inspection Hagens Berman (GlobeNewswire)
Oct-28-24 06:08PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
07:00AM	Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 (GlobeNewswire)
Oct-24-24 02:55PM	Humacyte (HUMA) Faces Questions After FDA Inspection Hagens Berman (GlobeNewswire)
Oct-23-24 08:00AM	Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV ) for AV Access in Hemodialysis on October 31, 2024 (GlobeNewswire)
Oct-16-24 08:00AM	Its Spare Parts for People: Blood Vessels Grown in a Lab (The Wall Street Journal)
Oct-08-24 08:00AM	Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 (GlobeNewswire)
06:30AM	Humacyte Launches $30M Stock and Warrants Offering (TipRanks)
Oct-04-24 08:00AM	Humacyte Announces Pricing of $30.0 Million Registered Direct Offering (GlobeNewswire)
Sep-26-24 05:26PM	Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV ) in Vascular Trauma Treatment on September 30, 2024 (GlobeNewswire)
Sep-19-24 08:00AM	Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP ) (GlobeNewswire)
Sep-03-24 08:00AM	Humacyte to Participate at Upcoming Investor Conferences in September (GlobeNewswire) -8.51%
Aug-27-24 08:00AM	Humacyte Presents Positive Long-Term Results of ATEV in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program (GlobeNewswire) -5.53%
Aug-13-24 07:00AM	Humacyte Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Aug-12-24 08:00AM	Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024 (GlobeNewswire) -16.37%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-09-24 04:05PM	Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV) BLA for the Treatment of Vascular Trauma (GlobeNewswire)
Jul-31-24 07:00AM	Humacyte Acellular Tissue Engineered Vessel (ATEV ) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis (GlobeNewswire) +15.37%
Jul-16-24 08:00AM	Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones (GlobeNewswire)
Jul-09-24 10:07AM	Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs (Business Wire)
Jul-01-24 08:00AM	Humacyte Acellular Tissue Engineered Vessel (ATEV ) Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD) (GlobeNewswire) +11.87%
Jun-25-24 08:00AM	Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP ) Program (GlobeNewswire)
Jun-17-24 08:00AM	Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte's Human Acellular Vessel (HAV ) (GlobeNewswire) -12.20%
Jun-03-24 07:01PM	Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA) (GuruFocus.com) -9.50%
May-30-24 08:00AM	Humacyte to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +18.03%
May-16-24 02:20PM	Hedge Fund and Insider Trading News: Michael Burry, Leon Cooperman, Ray Dalio, Stanley Druckenmiller, Millennium Management, Paulson & Co, Rokos Capital Management, Humacyte Inc (HUMA), GeneDx Holdings Corp. (WGS), and More (Insider Monkey)
May-13-24 08:00AM	Humacyte to Participate at Upcoming Investor Conferences in May (GlobeNewswire) +16.60%
May-10-24 02:43PM	Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances (GuruFocus.com)
11:54AM	HUMA Stock Earnings: Humacyte Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Humacyte First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:00AM	Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024 (GlobeNewswire)
Apr-21-24 08:39AM	10 Stocks American Politicians are Buying in 2024 (Insider Monkey)
Mar-26-24 04:05PM	Humacyte to Host Virtual KOL Event Hemodialysis Access: A Crossroads of Care, on March 28, 2024 (GlobeNewswire)
Mar-23-24 10:16AM	Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 11:53AM	HUMA Stock Earnings: Humacyte Meets EPS for Q4 2023 (InvestorPlace) -8.06%
07:00AM	Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update (GlobeNewswire)
Mar-19-24 08:58AM	Should You Buy Humacyte (HUMA) Ahead of Earnings? (Zacks)

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scheessele William John	Chief Commercial Officer	Apr 14 '25	Buy	1.54	6,493	9,999	22,018	Apr 15 04:03 PM
Sander Dale A.	CFO and Chief Corp. Deve. Off.	Apr 10 '25	Buy	1.53	20,000	30,600	40,600	Apr 14 09:00 AM
Parikh Shamik J	Chief Medical Officer	Apr 10 '25	Buy	1.55	7,500	11,625	7,500	Apr 14 09:00 AM
Sebelius Kathleen	Director	Apr 08 '25	Buy	1.32	50,000	66,000	91,207	Apr 08 04:15 PM
Green Charles Bruce	Director	Apr 08 '25	Buy	1.29	6,000	7,740	8,400	Apr 08 04:15 PM
Constantino Michael T.	Director	Apr 07 '25	Buy	1.26	16,000	20,160	32,950	Apr 08 04:15 PM
Constantino Michael T.	Director	Dec 04 '24	Buy	4.39	4,600	20,181	16,950	Dec 04 04:05 PM
Niklason Laura E	President, CEO and Director	Nov 19 '24	Buy	4.44	1,797	7,979	243,851	Nov 21 07:31 AM
Dougan Brady W	Director	Nov 19 '24	Buy	4.44	1,797	7,979	243,851	Nov 21 07:30 AM
Niklason Laura E	President, CEO and Director	Nov 18 '24	Sale	4.44	811,172	3,601,604	2,419,712	Nov 20 07:06 PM
Niklason Laura E	President, CEO and Director	Nov 19 '24	Sale	4.34	427,459	1,855,172	1,992,253	Nov 20 07:06 PM
Niklason Laura E	President, CEO and Director	Nov 20 '24	Sale	4.40	261,369	1,150,024	1,730,884	Nov 20 07:06 PM
Dougan Brady W	Director	Nov 18 '24	Sale	4.44	811,172	3,601,604	2,419,712	Nov 20 07:02 PM
Dougan Brady W	Director	Nov 19 '24	Sale	4.34	427,459	1,855,172	1,992,253	Nov 20 07:02 PM
Dougan Brady W	Director	Nov 20 '24	Sale	4.40	261,369	1,150,024	1,730,884	Nov 20 07:02 PM
AYABUDGE LLC	Director	Nov 20 '24	Proposed Sale	4.40	261,369	1,149,218		Nov 20 04:12 PM
AYABUDGE LLC	Director	Nov 19 '24	Proposed Sale	4.34	427,459	1,854,067		Nov 19 04:17 PM
AYABUDGE LLC	Director	Nov 18 '24	Proposed Sale	4.44	811,172	3,603,981		Nov 18 04:27 PM
Green Charles Bruce	Director	Sep 13 '24	Option Exercise	4.09	1,200	4,908	2,400	Sep 16 04:36 PM
Sebelius Kathleen	Director	Sep 10 '24	Option Exercise	3.99	7,000	27,926	43,910	Sep 11 05:53 PM
Sebelius Kathleen	Director	Sep 10 '24	Sale	5.40	5,182	28,004	40,276	Sep 11 05:53 PM
Dougan Brady W	Director	Sep 10 '24	Sale	5.23	288,674	1,509,765	3,230,884	Sep 11 05:52 PM
Dougan Brady W	Director	Sep 09 '24	Sale	5.42	157,704	854,756	3,519,558	Sep 11 05:52 PM
Niklason Laura E	President, CEO and Director	Sep 10 '24	Sale	5.23	288,674	1,509,765	3,230,884	Sep 11 05:50 PM
Niklason Laura E	President, CEO and Director	Sep 09 '24	Sale	5.42	157,704	854,756	3,519,558	Sep 11 05:50 PM
AYABUDGE LLC	Director	Sep 10 '24	Proposed Sale	5.23	288,674	1,510,584		Sep 10 04:19 PM
Sebelius Kathleen	Director	Sep 10 '24	Proposed Sale	5.41	5,182	28,012		Sep 10 10:41 AM
AYABUDGE LLC	Director	Sep 09 '24	Proposed Sale	5.42	157,704	855,153		Sep 09 04:19 PM
Niklason Laura E	President, CEO and Director	Aug 29 '24	Buy	6.54	1,222	7,998	242,054	Sep 03 04:23 PM
Dougan Brady W	Director	Aug 29 '24	Buy	6.54	1,222	7,998	242,054	Sep 03 04:17 PM
Dougan Brady W	Director	Aug 29 '24	Sale	6.35	352,112	2,235,911	3,677,262	Aug 29 06:52 PM
Dougan Brady W	Director	Aug 28 '24	Sale	6.47	277,090	1,792,772	4,029,374	Aug 29 06:52 PM
Dougan Brady W	Director	Aug 27 '24	Sale	6.71	252,676	1,695,456	4,306,464	Aug 29 06:52 PM
Niklason Laura E	President, CEO and Director	Aug 29 '24	Sale	6.35	352,112	2,235,911	3,677,262	Aug 29 06:48 PM
Niklason Laura E	President, CEO and Director	Aug 28 '24	Sale	6.47	277,090	1,792,772	4,029,374	Aug 29 06:48 PM
Niklason Laura E	President, CEO and Director	Aug 27 '24	Sale	6.71	252,676	1,695,456	4,306,464	Aug 29 06:48 PM
Sander Dale A.	CFO and Chief Corp. Deve. Off.	Aug 27 '24	Option Exercise	2.56	39,389	100,836	41,389	Aug 29 06:45 PM
Sander Dale A.	CFO and Chief Corp. Deve. Off.	Aug 27 '24	Sale	6.68	39,389	263,119	2,000	Aug 29 06:45 PM
AYABUDGE LLC	Director	Aug 29 '24	Proposed Sale	6.35	352,112	2,235,911		Aug 29 04:31 PM
Ayabudge LLC	Director	Aug 28 '24	Proposed Sale	6.47	277,090	1,792,772		Aug 28 04:12 PM
Ayabudge LLC	Director	Aug 27 '24	Proposed Sale	6.71	252,676	1,696,341		Aug 27 04:41 PM
Sander Dale A.	Officer	Aug 27 '24	Proposed Sale	6.68	39,389	263,311		Aug 27 01:09 PM
Constantino Michael T.	Director	Aug 15 '24	Buy	6.29	3,100	19,494	12,350	Aug 15 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HUMA

Humacyte Inc

Upgrade your FINVIZ experience